The invention relates to Raman and surface enhanced Raman-active bioassays or other reaction mixture. Particularly, the invention is directed to a method of separating an unattached Raman-active tag from a bioassay or other reaction mixture.
Raman and surface enhanced Raman-active tags 100 are known to detect the presence of pathogenic organisms or other materials.
Thus, a need still remains for a method of separating unattached Raman-active tag 100 from bioassay or other reaction mixture.
The purpose and advantages of embodiments of the invention will be set forth and apparent from the description that follows, as well as will be learned by practice of the embodiments of the invention. Additional advantages will be realized and attained by the methods and systems particularly pointed out in the written description and claims hereof, as well as from the appended drawings. An embodiment of the invention provides a super-paramagnetic Raman-active complex. The super-paramagnetic Raman-active complex includes a Raman-active tag attached to a target and a super-paramagnetic bead attached to the target.
A second embodiment provides a method of separating a Raman-active tag unattached to a target from a Raman-active complex. The Raman-active complex includes a Raman-active tag attached to a target. The method includes (i) providing a mixture comprising at least one Raman-active tag unattached to a target and at least one super-paramagnetic Raman-active complex and (ii) applying a magnetic field to the mixture.
A third embodiment provides a method of separating a surface-enhanced Raman-active tag unattached to a target from a Raman-active complex. The method includes (i) providing a mixture comprising at least one Raman-active tag unattached to a target and at least one super-paramagnetic Raman-active complex and (ii) applying a magnetic field to the mixture. The Raman-active complex includes a Raman-active tag attached to a target. The Raman-active tag includes a Raman-active particle and a target-binding moiety comprising an antibody
The accompanying figures, which are incorporated in and constitute part of this specification, are included to illustrate and provide a further understanding of the method and system of the invention. Together with the description, the drawings serve to explain the principles of the invention.
a is another schematic representation of Raman-active complex in accordance with an embodiment of the invention;
Reference will now be made in detail to exemplary embodiments of the invention, which are illustrated in the accompanying figures and examples. Referring to the drawings in general, it will be understood that the illustrations are for the purpose of describing a particular embodiment of the invention and are not intended to limit the invention thereto.
Whenever a particular embodiment of the invention is said to comprise or consist of at least one element of a group and combinations thereof, it is understood that the embodiment may comprise or consist of any of the elements of the group, either individually or in combination with any of the other elements of that group. Furthermore, when any variable occurs more than one time in any constituent or in formula, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
With reference to
In one embodiment, the Raman-active tag 100 is immuno-functionalized. Immuno-functionalized Raman-active tags 100 detect the presence of one or more targets 212 that are pathogenic organisms or other materials. Immuno-functionalized Raman-active tags 100 include Raman-active tags 100 attached to one or more target-binding moieties 112 that are antibodies. The target-binding moiety 112 is configured to allow the Raman-active tag 100 to attach to a target 212 to form a Raman-active complex 200. Attached means the target-binding moiety 112 is covalently or non-covalently connected to a target 212. Examples of other target-binding moieties 112 include, but are not limited to, antibodies, aptamers, polypeptides, nucleic acid, peptide nucleic acids, avidin, streptavidin, and derivatives of avidin and streptavidin. The Raman-active tag 100 may comprise one target-binding moiety 112 or a plurality of target-binding moieties 112, as in
Examples of targets 212 to which a target-binding moiety 112 may attach include, but are not limited to, organisms such as viruses, bacteria, yeast, spores, liposomes, proteins, polypeptides, toxins, nucleic acids, and beads. Examples of beads include, but are not limited to, latex, polystyrene, silica and plastic. In one embodiment, a target 212 is attached to one Raman-active complex 200 as in
With reference to
As described in
In one embodiment of providing the super-paramagnetic Raman-active complexes 300, the super-paramagnetic Raman-active complexes 300 are provided by providing one or more super-paramagnetic beads 310, one or more Raman-active tags 100, and one or more targets 212. The super-paramagnetic beads 310, Raman-active tags 100, and targets 212 attach together to form the super-paramagnetic Raman-active complexes 300. The method is not limited by how the super-paramagnetic beads 310, Raman-active tags 100, and targets 212 attach. Examples of attaching include, but are not restricted to, electrostatically, chemically, and physically. The super-paramagnetic beads 310 and target may also attach together to form a super-paramagnetic-target complex 400.
The super-paramagnetic beads 310, Raman-active tags 100, and targets 212 may be provided simultaneously, as in
Next, Step 615 includes applying a magnetic field to the mixture. The magnetic field immobilizes the super-paramagnetic beads 310 as well as the super-paramagnetic Raman-active complex 300 which comprises the super-paramagnetic beads 310, the target 212, and Raman-active tags 100. In one embodiment of applying a magnetic field, the super-paramagnetic beads 310 are in a range from about 10 nm to about 10 microns. In another embodiment of applying a magnetic field, the super-paramagnetic beads 310 are in a range from about 0.3 micron to about 1.5 microns.
The method may also further comprise taking a Raman spectrum of the super-paramagnetic Raman-active complex 300. The Raman spectrum may be taken directly after a washing Step 625 to remove any unattached Raman-active tags 100 and other non-target 500 components of the mixture that are in solution. The super-paramagnetic Raman-active complexes 300 are then removed from the magnetic field and resuspended in a small volume of buffer to take the Raman spectrum.
The following example serves to illustrate the features and advantages of the invention and is not intended to limit the invention thereto.
Magnetic Particle Method Example (Generalized):
A sample of target microorganisms 212, which includes but is not restricted to bacteria, spores, and viruses, is added to a sample container such as an eppindorf tube.
A quantity of nanometer or micrometer sized super-paramagnetic (SPR) beads 310 attached to antibodies against the target microorganism 212 are added to the sample.
A quantity of Raman-active tags 100 attached to antibodies against the target microorganism 212 is added to the sample.
The sample is mixed and incubated at room temperature for a period of time.
The mixture is placed in a magnetic field. The magnetic field immobilizes the SPR particles 310, as well as the super-paramagnetic Raman-active complex 300 which comprises the SPR bead 310, the target 212, and Raman-active tags 100. The magnetic field immobilizes the SPR bead and the super-paramagnetic Raman-active complex 300 onto the wall of the tube 310.
Unattached Raman-active tags and other components of the mixture remain in solution and are removed by washing.
After washing, the super-paragmagnetic Raman-active complex 300 (i.e. SPR-Target-Raman-active complexes) are removed from the magnetic field and resuspended in a small volume of buffer.
A portion of the buffer is then analyzed for the presence of a Raman-active signal.
Thus, Example 1 demonstrates how it is possible to use immuno-functionalized Raman-active tags 100 to detect the presence of a specific target organism 212. In these experiments, a Raman signal is only detected when the appropriate target organism 212 and Raman-active tags 100 immuno-functionalized for that specific target organism 212 to detect the presence of that specific target organism 212 are both present.
While the invention has been described in detail in connection with only a limited number of aspects, it should be readily understood that the invention is not limited to such disclosed aspects. Rather, the invention can be modified to incorporate any number of variations, alterations, substitutions or equivalent arrangements not heretofore described, but which are commensurate with the spirit and scope of the invention. Additionally, while various embodiments of the invention have been described, it is to be understood that aspects of the invention may include only some of the described embodiments. Accordingly, the invention is not to be seen as limited by the foregoing description, but is only limited by the scope of the appended claims.